Not available
Quote | Blueprint Medicines Corporation (NASDAQ:BPMC)
Last: | $94.86 |
---|---|
Change Percent: | -0.22% |
Open: | $95 |
Close: | $94.86 |
High: | $95.98 |
Low: | $93.5 |
Volume: | 646,740 |
Last Trade Date Time: | 03/28/2024 03:00:00 am |
News | Blueprint Medicines Corporation (NASDAQ:BPMC)
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...
Message Board Posts | Blueprint Medicines Corporation (NASDAQ:BPMC)
Subject | By | Source | When |
---|---|---|---|
Why the drop today...the news release seems positive...anyone | ziggy7796 | investorshub | 08/17/2022 2:40:48 PM |
BPMC buy 98.69 | stocktrademan | investorshub | 09/12/2021 4:19:19 AM |
Blueprint Medicines Corp. | TFMG | investorshub | 06/21/2020 6:15:20 PM |
Avapritinib Today is the date | Frankestin | investorshub | 05/14/2020 10:35:40 AM |
Sold near EOD @ $59.60. Earnings pre-market tomorrow. | chmcnfunds | investorshub | 07/31/2018 7:58:12 PM |
News, Short Squeeze, Breakout and More Instantly...
Blueprint Medicines Corporation Company Name:
BPMC Stock Symbol:
NASDAQ Market:
Blueprint Medicines Corporation Website:
CAMBRIDGE, Mass., March 6, 2024 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ:BPMC), today announced that, effective March 1, 2024, the C...
2024-02-29 12:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Blueprint Medicines Highlights AYVAKIT® (avapritinib) Long-Term Efficacy and Safety Data and Advances in Mast Cell Disease Research at 2024 AAAAI Annual Meeting PR Newswire -- AYVAKIT data in patients with indolent systemic mastocytosis show durable efficacy and favorable...